California-based Ikänik Farms Inc. has partnered with CAS Biotechnology to study the effects of pharmaceutical-grade cannabis oil in the treatment of COVID-19.
Under the collaboration deal, Ikänik opted to export the pharmaceutical-grade cannabis provided by its Colombia-based GACP and GMP-Pharma certified Casa Flores facility to Mexico.
The company said Monday that CAS Biotechnology's team would be responsible for testing samples provided by Pideka SAS.
The Mexico-based CAS Biotechnology will oversee scientific research and pre-clinical trials to evaluate the effect of Cannabis oil on SARS-CoV-2's replication cycle.
Ikänik International's President Borja Sanz de Madrid is thrilled with the new partnership while hoping to "aid in the treatment of COVID-19."
"We are very proud to participate in a study that brings medicine and cannabis closer together, in a joint effort to discover possible Phyto therapeutic treatments, as a new course of action for the treatment of COVID-19," Ikänik CEO Brian Baca said.
Earlier this month, the company acquired Delta 9 Corporation Mexico in order to export hemp and cannabis products to Mexico legally.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.